Skip to main content
Sign in Create a free account
Varsity Tutors
Sign in

Patient Parameters And Laboratory Measures - NAPLEX

  1. A 61-year-old female (weight 70 kg) with DVT on warfarin presents for routine INR monitoring. Medical history: DVT (6 months ago), hypothyroidism. Current medications: warfarin 6 mg PO daily, levothyroxine 100 mcg PO daily; she reports starting a "keto" diet with markedly increased leafy green vegetable intake over the last 2 weeks. Allergies: none. Labs: INR 1.7 (goal 2–3), Hgb 12.9 g/dL, platelets 230k, SCr 0.9 mg/dL. What is the next best step in managing this patient's anticoagulation therapy?
    Answer: Counsel on consistent vitamin K intake and consider increasing weekly warfarin dose with closer INR follow-up This question tests the impact of dietary vitamin K changes on warfarin therapy and INR management. The key patient-specific factor is the 61-year-old female's increased leafy green intake on a keto diet, leading to subtherapeutic INR of 1.7 due to vitamin K antagonism of warfarin. Counseling on consistent vitamin K intake and considering warfarin dose increase with follow-up is the best step to stabilize INR. Holding warfarin or adding aspirin is inappropriate, and vitamin K administration would lower INR further. Distractors overlook dietary influence. A clinical pearl is to maintain consistent vitamin K intake and adjust warfarin based on trends. This approach improves anticoagulation stability.
  2. A 72-year-old female (weight 52 kg, height 160 cm) presents to the ED with dysuria and fever and is diagnosed with pyelonephritis; the provider wants to start levofloxacin. Current medications: metformin ER 1000 mg PO BID, lisinopril 20 mg PO daily, atorvastatin 20 mg PO nightly, aspirin 81 mg PO daily. PMH: type 2 diabetes, HTN, hyperlipidemia. Allergies: penicillin (rash). Labs: SCr 2.1 mg/dL, BUN 38 mg/dL, K 4.8 mEq/L, Na 138 mEq/L, AST 22 U/L, ALT 18 U/L, INR 1.0; estimated CrCl by Cockcroft–Gault is approximately 20 mL/min. Based on the lab results, which medication adjustment is needed?
    Answer: Start levofloxacin 750 mg PO once, then 750 mg PO every 48 hours due to reduced CrCl This question tests the ability to calculate creatinine clearance and apply appropriate renal dosing adjustments for antibiotics in elderly patients. The key patient-specific factor is the severely reduced CrCl of approximately 20 mL/min in this 72-year-old female with pyelonephritis. Option B is correct because levofloxacin requires significant dose adjustment when CrCl is 20-49 mL/min - specifically, the standard 750 mg dose is given initially, followed by 750 mg every 48 hours instead of daily. Option A is incorrect as it fails to account for the renal impairment, risking drug accumulation and toxicity. Option C incorrectly suggests more frequent dosing with a lower dose, which is not the standard renal adjustment for levofloxacin. Option D is incorrect because penicillin allergy does not contraindicate fluoroquinolones - these are structurally unrelated drug classes. When adjusting fluoroquinolone doses for renal impairment, maintain the same individual dose but extend the dosing interval to prevent accumulation while ensuring adequate peak concentrations for bacterial killing.
  3. A 65-year-old male (weight 84 kg) with gout is prescribed allopurinol 300 mg PO daily. Medical history: gout, CKD stage 3b, HTN. Current medications: allopurinol (new), colchicine 0.6 mg PO daily PRN flares, losartan 100 mg PO daily. Allergies: none. Labs: SCr 2.0 mg/dL, eGFR 34 mL/min/1.73 m2^2, AST/ALT WNL, K 4.5 mEq/L. What is the most appropriate therapy given the patient's renal function?
    Answer: Start allopurinol 100 mg PO daily and titrate based on uric acid and tolerability This question tests allopurinol dosing initiation in gout patients with renal impairment to prevent hypersensitivity. The key patient-specific factor is the 65-year-old male's CKD stage 3b with eGFR 34 mL/min, requiring low starting dose. Starting allopurinol 100 mg PO daily with titration is best per guidelines to minimize risks in CKD. Standard 300 mg or high 600 mg risks toxicity, and probenecid is not preferred in CKD due to inefficacy. Distractors ignore renal adjustment. A clinical pearl is to start low and go slow with allopurinol in CKD, targeting uric acid <6 mg/dL. This framework enhances gout control safety.
  4. A 58-year-old male (weight 82 kg) with HFpEF and HTN presents with weakness and palpitations. Current medications: spironolactone 25 mg PO daily, lisinopril 20 mg PO daily, furosemide 20 mg PO daily, metoprolol succinate 50 mg PO daily. Medical history: CKD stage 3a, HFpEF. Allergies: none. Labs: K 6.1 mEq/L (normal 3.5–5.0), SCr 1.7 mg/dL, Na 136 mEq/L, CO2_2 22 mEq/L, AST/ALT WNL. How should the pharmacist manage this patient's electrolyte imbalance?
    Answer: Hold spironolactone and lisinopril and urgently notify the prescriber due to hyperkalemia This question tests the recognition and management of hyperkalemia in heart failure patients on RAAS inhibitors. The key patient-specific factor is the 58-year-old male's serum potassium of 6.1 mEq/L with symptoms like weakness and palpitations, alongside CKD stage 3a. Holding spironolactone and lisinopril and urgently notifying the prescriber is the best action to prevent life-threatening arrhythmias from hyperkalemia. Adding potassium supplementation is contraindicated, increasing spironolactone ignores the electrolyte imbalance, and switching furosemide to hydrochlorothiazide does not address the hyperkalemia cause. Distractors fail to prioritize immediate RAAS inhibitor discontinuation. A clinical pearl is to monitor potassium frequently in HF patients on ACEIs/ARBs and aldosterone antagonists, especially with CKD. This approach helps balance HF management with electrolyte safety.
  5. A 73-year-old male (weight 65 kg) with chronic pain is prescribed morphine ER 30 mg PO q12h. Medical history: CKD stage 4, COPD. Current medications: albuterol inhaler PRN, tiotropium inhaler daily, morphine ER (new). Allergies: codeine (nausea). Labs: SCr 2.9 mg/dL, eGFR 20 mL/min/1.73 m2^2, Na 140 mEq/L, K 4.4 mEq/L, AST/ALT WNL. What is the most appropriate therapy given the patient's renal function?
    Answer: Recommend an alternative opioid with less active metabolite accumulation in CKD (e.g., hydromorphone) and use cautious dosing This question tests opioid selection and dosing in chronic kidney disease to avoid metabolite toxicity. The key patient-specific factor is the 73-year-old male's CKD stage 4 with eGFR 20 mL/min, where morphine metabolites accumulate. Recommending an alternative like hydromorphone with cautious dosing is best to minimize risks like respiratory depression. Proceeding with morphine is unsafe, increasing dose compensates incorrectly, and adding naproxen risks renal worsening. Distractors overlook metabolite issues. A clinical pearl is to prefer opioids like fentanyl or hydromorphone in advanced CKD. This framework ensures safer pain control in renal impairment.
  6. A 54-year-old male (weight 100 kg) is evaluated for dyslipidemia. Medical history: HTN, smoker; no ASCVD. Current medications: losartan 50 mg PO daily. Allergies: none. Labs: total cholesterol 210 mg/dL, LDL 132 mg/dL, HDL 38 mg/dL, TG 180 mg/dL, AST 22 U/L, ALT 25 U/L, SCr 1.0 mg/dL. Based on the lab results, what is the most appropriate therapy?
    Answer: Start atorvastatin 20 mg PO nightly This question tests primary prevention lipid management in patients with multiple risk factors. The key patient-specific factor is the 54-year-old male's smoking and HTN with LDL 132 mg/dL, warranting moderate-intensity statin. Starting atorvastatin 20 mg nightly is best per ACC/AHA for 10-year ASCVD risk ≥7.5%. Atorvastatin 80 mg is excessive for primary prevention, omega-3 monotherapy ignores statin priority, and withholding overlooks risk. Distractors misapply guidelines. A clinical pearl is to calculate ASCVD risk score for statin decisions. This framework optimizes prevention strategies.
  7. A 57-year-old female (weight 62 kg) with asthma is prescribed oseltamivir for influenza. Medical history: asthma, CKD stage 4. Current medications: budesonide-formoterol inhaler 2 puffs BID, albuterol inhaler PRN. Allergies: none. Labs: SCr 2.7 mg/dL, eGFR 18 mL/min/1.73 m2^2, AST/ALT WNL. The prescriber orders oseltamivir 75 mg PO BID for 5 days. What is the most appropriate therapy given the patient's renal function?
    Answer: Reduce oseltamivir dose/frequency (e.g., 30 mg PO daily) based on renal impairment This question tests antiviral dosing adjustments in severe renal impairment for influenza treatment. The key patient-specific factor is the 57-year-old female's CKD stage 4 with eGFR 18 mL/min, necessitating oseltamivir reduction. Reducing to 30 mg PO daily is best per guidelines for CrCl <30 mL/min to avoid accumulation. Continuing standard dose risks toxicity, increasing dose is counterproductive, and amantadine is not preferred due to resistance. Distractors ignore renal clearance. A clinical pearl is to adjust oseltamivir based on CrCl for short courses in CKD. This approach ensures effective and safe antiviral therapy.
  8. A 64-year-old male (weight 90 kg) with type 2 diabetes presents for follow-up due to elevated home glucose readings. Medical history: T2DM, HTN, ASCVD (prior MI). Current medications: metformin 1000 mg PO BID, glipizide IR 10 mg PO BID, lisinopril 10 mg PO daily, atorvastatin 40 mg PO nightly, aspirin 81 mg PO daily. Allergies: none. Labs: A1c 9.2%, fasting glucose 198 mg/dL, SCr 1.0 mg/dL, eGFR 82 mL/min/1.73 m2^2, AST 28 U/L, ALT 31 U/L, LDL 68 mg/dL. Based on the lab results, which medication adjustment is needed?
    Answer: Add empagliflozin 10 mg PO daily This question tests the management of type 2 diabetes in patients with atherosclerotic cardiovascular disease and suboptimal glycemic control. The key patient-specific factor is the 64-year-old male's history of ASCVD (prior MI) and elevated A1c of 9.2% despite current therapy. Adding empagliflozin 10 mg PO daily is the best choice as SGLT2 inhibitors are recommended for T2DM patients with ASCVD to reduce cardiovascular risk and improve glycemic control. Increasing metformin to 1500 mg BID is suboptimal without addressing CV risk, stopping metformin for insulin monotherapy overlooks combination therapy benefits, and adding sitagliptin 25 mg is incorrect as the dose is renally adjusted unnecessarily given normal eGFR. No distractor addresses the CV benefit priority. A clinical pearl is to prioritize agents like SGLT2 inhibitors or GLP-1 agonists in T2DM with ASCVD per ADA guidelines. This approach integrates patient comorbidities into therapy selection for better outcomes.
  9. A 56-year-old female (weight 72 kg) with bipolar disorder is taking lithium. Medical history: bipolar I disorder, HTN. Current medications: lithium carbonate 300 mg PO TID, hydrochlorothiazide 25 mg PO daily (started 1 month ago). Allergies: none. Labs: lithium level 1.8 mEq/L (therapeutic 0.6–1.2), SCr 1.2 mg/dL, Na 134 mEq/L, TSH 2.1 mIU/L. She reports tremor and nausea. Based on the lab results, which medication adjustment is needed?
    Answer: Hold lithium and notify prescriber; evaluate stopping hydrochlorothiazide due to increased lithium levels This question tests lithium toxicity recognition and management in the context of drug interactions. The key patient-specific factor is the 56-year-old female's elevated lithium level of 1.8 mEq/L with symptoms, following hydrochlorothiazide initiation which reduces lithium clearance. Holding lithium and evaluating stopping hydrochlorothiazide is the best adjustment to resolve toxicity. Continuing or increasing lithium ignores toxicity, and adding NSAIDs would worsen levels. Distractors miss interaction. A clinical pearl is to monitor lithium levels closely with diuretics or NSAIDs. This approach prevents severe neurotoxicity in bipolar management.
  10. A 60-year-old female (weight 68 kg) with known cirrhosis due to hepatitis C is seen for insomnia and anxiety. Current medications: lactulose 20 g PO TID (titrate to 3 BMs/day), furosemide 40 mg PO daily, spironolactone 100 mg PO daily, propranolol 20 mg PO BID. PMH: decompensated cirrhosis with ascites and prior hepatic encephalopathy. Allergies: NKDA. Labs: albumin 2.6 g/dL, total bilirubin 3.2 mg/dL, INR 1.9, AST 78 U/L, ALT 55 U/L, SCr 1.1 mg/dL, Na 132 mEq/L. Based on the lab results, which medication adjustment is needed?
    Answer: Avoid benzodiazepines and recommend nonpharmacologic sleep measures due to high encephalopathy risk This question tests medication safety in hepatic impairment, specifically benzodiazepine use in decompensated cirrhosis. The critical lab values indicating severe liver dysfunction include albumin 2.6 g/dL, bilirubin 3.2 mg/dL, and INR 1.9, with a history of hepatic encephalopathy. Option B is correct because benzodiazepines are contraindicated in patients with cirrhosis and prior hepatic encephalopathy, as they significantly increase the risk of precipitating encephalopathy by enhancing GABAergic neurotransmission. Option A is incorrect and dangerous - diazepam's long half-life and active metabolites make it particularly hazardous in liver disease. Option C is incorrect as propranolol dose adjustment isn't indicated based on INR, and the current dose is appropriate for variceal prophylaxis. Option D is incorrect because lactulose is essential for preventing hepatic encephalopathy and doesn't increase bleeding risk. In cirrhotic patients with insomnia, recommend sleep hygiene, melatonin, or hydroxyzine while avoiding all benzodiazepines and other sedatives that can precipitate encephalopathy.
  11. A 75-year-old male (weight 72 kg) with atrial fibrillation is taking warfarin. Medical history: AFib, osteoarthritis. Current medications: warfarin 4 mg PO daily, acetaminophen 650 mg PO q6h PRN, and he started ibuprofen 600 mg PO TID OTC for knee pain 5 days ago. Allergies: none. Labs today: INR 3.9 (goal 2–3), Hgb 13.0 g/dL, platelets 200k, SCr 1.1 mg/dL. What is the next best step in managing this patient's anticoagulation therapy?
    Answer: Assess bleeding risk, recommend stopping NSAID, and adjust/hold warfarin dose with closer INR follow-up This question tests the management of warfarin-NSAID interactions and elevated INR. The key patient-specific factor is the 75-year-old male's recent ibuprofen use, which potentiates warfarin via platelet inhibition and displacement, causing INR 3.9. Assessing bleeding risk, stopping NSAID, and adjusting warfarin with follow-up is the best step to mitigate risks. Continuing both ignores interaction, high-dose vitamin K is for major bleeding, and increasing warfarin is counterproductive. Distractors miss synergy. A clinical pearl is to avoid NSAIDs in warfarin patients; use acetaminophen instead. This approach reduces bleeding complications.
  12. A 47-year-old male (weight 85 kg) with epilepsy is taking phenytoin. Medical history: seizure disorder, alcoholic cirrhosis. Current medications: phenytoin ER 300 mg PO nightly, lactulose 20 g PO BID. Allergies: none. Labs: total phenytoin level 12 mcg/mL (therapeutic 10–20), albumin 2.0 g/dL (normal 3.5–5.0), AST 85 U/L, ALT 60 U/L, INR 1.7, SCr 0.9 mg/dL. Which laboratory value indicates a need for therapy modification?
    Answer: Albumin 2.0 g/dL This question assesses the interpretation of phenytoin levels in the context of altered protein binding, particularly in liver disease. The critical patient-specific factor is the low albumin level of 2.0 g/dL, which is well below the normal range of 3.5–5.0 g/dL due to alcoholic cirrhosis. Choice B is the most appropriate because hypoalbuminemia increases the free fraction of highly protein-bound phenytoin, potentially leading to supratherapeutic free levels despite a normal total level, necessitating therapy modification such as dose reduction after correction. Choice A is incorrect as the total phenytoin level of 12 mcg/mL appears therapeutic but is misleading without albumin correction, which would estimate a higher effective level. Choice C is not relevant since the serum creatinine of 0.9 mg/dL is normal and does not impact phenytoin dosing, and choice D is suboptimal because the mildly elevated ALT of 60 U/L indicates liver dysfunction but does not directly mandate phenytoin adjustment without considering binding effects. A useful clinical pearl is to apply the phenytoin correction formula—corrected level = total level / [(0.2 × albumin) + 0.1]—in patients with hypoalbuminemia to avoid toxicity. For similar cases, adopt a framework that accounts for protein binding alterations in liver disease when monitoring highly bound antiepileptics, ensuring accurate therapeutic decisions.
  13. A 72-year-old female (weight 58 kg) presents with confusion and unsteady gait. Medical history: SIADH, depression, HTN. Current medications: sertraline 100 mg PO daily, hydrochlorothiazide 25 mg PO daily, amlodipine 5 mg PO daily. Allergies: none. Labs: Na 122 mEq/L (normal 135–145), K 3.7 mEq/L, SCr 0.9 mg/dL, serum osmolality low; AST/ALT WNL. How should the pharmacist manage this patient's electrolyte imbalance?
    Answer: Hold hydrochlorothiazide and notify the prescriber due to symptomatic hyponatremia This question tests the identification and management of drug-induced hyponatremia in susceptible patients. The key patient-specific factor is the 72-year-old female's symptomatic hyponatremia (Na 122 mEq/L) with SIADH history and recent hydrochlorothiazide use. Holding hydrochlorothiazide and notifying the prescriber is the best action as thiazides can exacerbate hyponatremia in SIADH. Continuing the regimen with water intake is insufficient for symptomatic cases, adding desmopressin worsens hyponatremia, and potassium supplementation does not correct sodium. Distractors ignore thiazide's role. A clinical pearl is to suspect thiazides in elderly hyponatremia and monitor electrolytes closely. This framework aids in prompt electrolyte disorder resolution.
  14. A 52-year-old male (weight 88 kg) presents for primary prevention of ASCVD. Current medications: none. PMH: tobacco use (1 pack/day), HTN (untreated). Allergies: NKDA. Labs: total cholesterol 252 mg/dL, LDL 176 mg/dL, HDL 38 mg/dL, triglycerides 210 mg/dL, A1c 5.6%, AST 26 U/L, ALT 22 U/L, SCr 1.0 mg/dL. Based on the lab results, which medication adjustment is needed?
    Answer: Initiate high-intensity statin therapy (e.g., atorvastatin 40–80 mg PO daily) This question tests application of ASCVD risk assessment and statin intensity selection for primary prevention based on multiple risk factors. The key parameters are LDL 176 mg/dL, HDL 38 mg/dL, current smoking, and untreated hypertension in a 52-year-old male. Option A is correct because this patient has multiple major ASCVD risk factors (smoking, hypertension, low HDL) with an LDL 70-189 mg/dL, indicating need for high-intensity statin therapy to achieve ≥50% LDL reduction. Option B is incorrect as low-intensity statins are inadequate given his high ASCVD risk and would achieve only 20-30% LDL reduction. Option C is incorrect because statins are first-line for LDL reduction and ASCVD prevention; fibrates are not appropriate monotherapy despite elevated triglycerides. Option D is incorrect - normal A1c doesn't negate the need for lipid therapy given his other significant risk factors. For primary prevention, calculate 10-year ASCVD risk and consider risk enhancers like smoking; this patient likely has >20% 10-year risk warranting high-intensity statin therapy.
  15. A 60-year-old male (weight 92 kg) is evaluated for lipid therapy. Medical history: prior ischemic stroke, HTN. Current medications: clopidogrel 75 mg PO daily, lisinopril 20 mg PO daily. Allergies: none. Labs: LDL 156 mg/dL, total cholesterol 240 mg/dL, HDL 41 mg/dL, TG 210 mg/dL, AST 26 U/L, ALT 30 U/L, SCr 1.0 mg/dL. Based on the lab results, what is the most appropriate therapy?
    Answer: Start atorvastatin 80 mg PO nightly This question tests statin intensity selection for secondary prevention in patients with atherosclerotic cardiovascular disease. The key patient-specific factor is the 60-year-old male's prior ischemic stroke, classifying him as very high risk requiring high-intensity statin. Starting atorvastatin 80 mg PO nightly is the best choice per ACC/AHA guidelines to achieve ≥50% LDL reduction. Pravastatin 10 mg is low-intensity, fenofibrate monotherapy ignores statin priority, and withholding ignores ASCVD. Distractors undervalue intensity needs. A clinical pearl is to maximize statin dose in ASCVD before adding non-statins. This approach optimizes CV risk reduction.
  16. A 50-year-old male (weight 78 kg) with alcohol use disorder and suspected alcoholic hepatitis presents for medication review. Medical history: alcoholic hepatitis, insomnia. Current medications: zolpidem 10 mg PO nightly PRN, acetaminophen 500 mg PO q6h PRN, multivitamin daily. Allergies: none. Labs: AST 210 U/L (normal 10–40), ALT 95 U/L (normal 7–56), total bilirubin 2.8 mg/dL (normal 0.2–1.2), INR 1.6 (normal 0.9–1.1), albumin 2.9 g/dL (normal 3.5–5.0), SCr 0.8 mg/dL. Based on the lab results, which medication adjustment is needed?
    Answer: Recommend lowering zolpidem dose (e.g., 5 mg nightly) due to hepatic impairment and CNS risk This question tests medication adjustments in hepatic impairment to reduce adverse effects. The key patient-specific factor is the 50-year-old male's alcoholic hepatitis with elevated LFTs and INR, increasing zolpidem's half-life. Recommending zolpidem 5 mg nightly is best to minimize CNS depression in liver disease. Continuing 10 mg ignores impairment, starting disulfiram is premature, and increasing acetaminophen risks hepatotoxicity. Distractors overlook hepatic metabolism. A clinical pearl is to halve doses of sedatives like zolpidem in cirrhosis. This framework promotes safe insomnia management in liver disease.
  17. A 62-year-old female (weight 74 kg) is being evaluated for hyperlipidemia. Medical history: T2DM, HTN; no known ASCVD. Current medications: metformin 1000 mg PO BID, amlodipine 10 mg PO daily. Allergies: none. Labs: total cholesterol 262 mg/dL, LDL 178 mg/dL, HDL 44 mg/dL, TG 190 mg/dL, A1c 7.1%, AST 24 U/L, ALT 20 U/L, SCr 0.8 mg/dL. Based on the lab results, what is the most appropriate therapy?
    Answer: Start atorvastatin 40 mg PO nightly This question tests lipid management guidelines for patients with type 2 diabetes and elevated cardiovascular risk. The key patient-specific factor is the 62-year-old female's T2DM without ASCVD but with LDL of 178 mg/dL, warranting high-intensity statin therapy. Starting atorvastatin 40 mg PO nightly is the best choice as ACC/AHA guidelines recommend moderate- to high-intensity statins for diabetic patients aged 40-75 to reduce ASCVD risk. Starting ezetimibe as monotherapy is suboptimal without statin trial, niacin is not first-line due to side effects, and withholding therapy ignores elevated LDL despite TG <500 mg/dL. Distractors overlook statin priority in diabetes. A clinical pearl is to target LDL reduction of at least 50% with high-intensity statins in high-risk diabetics. This framework integrates risk assessment into lipid therapy decisions.
  18. A 68-year-old female (weight 55 kg) with osteoporosis is prescribed alendronate 70 mg PO weekly. Medical history: osteoporosis, CKD stage 4, GERD. Current medications: omeprazole 20 mg PO daily, calcium carbonate 500 mg PO BID, alendronate (new). Allergies: none. Labs: SCr 2.6 mg/dL, eGFR 20 mL/min/1.73 m2^2, Ca 9.0 mg/dL, 25-OH vitamin D 28 ng/mL. What is the most appropriate therapy given the patient's renal function?
    Answer: Avoid alendronate due to severe renal impairment and recommend an alternative osteoporosis strategy This question tests the management of osteoporosis in patients with chronic kidney disease, specifically the appropriateness of bisphosphonate therapy based on renal function. The key patient-specific factor is the estimated glomerular filtration rate (eGFR) of 20 mL/min/1.73 m², indicating CKD stage 4 with severe renal impairment. Choice B is the best option because alendronate is contraindicated in patients with eGFR less than 35 mL/min due to its renal elimination and risk of accumulation leading to toxicity, necessitating avoidance and consideration of alternatives like denosumab or teriparatide. Choice A is incorrect as bisphosphonates are not safe at any eGFR and can worsen renal function in severe impairment. Choice C is suboptimal because increasing the dose would heighten the risk of adverse effects rather than compensate for reduced clearance, and choice D is wrong since switching to daily dosing does not reduce renal risk and the drug remains contraindicated. A practical clinical pearl is to always assess eGFR prior to initiating bisphosphonates, as they are primarily excreted unchanged by the kidneys. In similar scenarios, use a framework that evaluates renal function against drug-specific thresholds to guide selection of osteoporosis therapies, prioritizing patient safety.
  19. A 69-year-old female (weight 63 kg) with T2DM presents for follow-up. Medical history: T2DM, ASCVD (PAD), CKD stage 2. Current medications: metformin 1000 mg PO BID, semaglutide 0.5 mg SC weekly, atorvastatin 40 mg PO nightly, aspirin 81 mg PO daily. Allergies: none. Labs: A1c 6.7%, fasting glucose 118 mg/dL, SCr 0.9 mg/dL, eGFR 72 mL/min/1.73 m2^2, LDL 62 mg/dL, AST/ALT WNL. Based on the lab results, which medication adjustment is needed?
    Answer: Continue current diabetes regimen; no adjustment is needed based on A1c This question tests glycemic goal assessment in type 2 diabetes with comorbidities. The key patient-specific factor is the 69-year-old female's A1c of 6.7% with ASCVD and CKD, which is at or below individualized goals. Continuing the current regimen without adjustment is best as A1c is controlled without hypoglycemia risk. Increasing semaglutide or adding glyburide is unnecessary, and stopping metformin overlooks its benefits. Distractors assume stricter goals. A clinical pearl is to individualize A1c targets to <7-8% in elderly with comorbidities per ADA. This approach balances control and safety.
  20. A 52-year-old male (weight 86 kg) with hypertension is started on lisinopril 10 mg PO daily. Medical history: HTN, T2DM. Current medications: lisinopril (new), metformin 1000 mg PO BID. Allergies: none. Baseline labs: SCr 0.9 mg/dL, K 4.3 mEq/L. Two weeks later labs: SCr 1.3 mg/dL, K 5.6 mEq/L (normal 3.5–5.0), Na 138 mEq/L. Which laboratory value indicates a need for therapy modification?
    Answer: K 5.6 mEq/L This question tests the monitoring of adverse effects from ACE inhibitors like hyperkalemia. The key patient-specific factor is the 52-year-old male's rise in potassium to 5.6 mEq/L after starting lisinopril, indicating RAAS inhibition effect. The K 5.6 mEq/L value indicates a need for modification such as holding or adjusting lisinopril to prevent arrhythmias. Na 138 is normal, SCr 1.3 represents mild AKI but secondary, and weight is irrelevant. Distractors are non-critical changes. A clinical pearl is to check electrolytes 1-2 weeks after starting ACEIs, especially in diabetics. This framework prevents hyperkalemia complications.

Start this quiz